rosiglitazone has been researched along with sodium glutamate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ | 1 |
| Chen, W; Liu, HY; Wang, LL; Zhang, LH; Zhou, XB | 1 |
2 other study(ies) available for rosiglitazone and sodium glutamate
| Article | Year |
|---|---|
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expression; Gluconeogenesis; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Glycogen; Muscles; Obesity; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Propionates; Pyrimidines; Rats; Rats, Wistar; Rosiglitazone; Sodium Glutamate; Thiazolidinediones | 2006 |
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Weight; Drug Synergism; Eating; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipids; Lipoprotein Lipase; Liver; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Rosiglitazone; Sodium Glutamate; Thiazolidinediones | 2010 |